# De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

> **NCT07303686** · PHASE4 · RECRUITING · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 115 (estimated)

## Conditions studied

- Crohn Disease (CD)
- Ulcerative Colitis (UC)

## Interventions

- **BIOLOGICAL:** Ustekinumab 90 mg SC q8w
- **BIOLOGICAL:** Ustekinumab 90 mg SC q12w

## Key facts

- **NCT ID:** NCT07303686
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-08
- **Primary completion:** 2027-04-15
- **Final completion:** 2027-10-15
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07303686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07303686, "De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07303686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*